On a disclosed basis, revenue rose from KRW 9.15 billion in 2022 to KRW 12.4 billion in 2023 (up 35.7% year on year) and KRW 13.1 billion in 2024 (up 5.6%), then reached KRW 26.2 billion in 2025 (up 100.2%).
Revenue has risen for three consecutive years from 2023 through 2025, and 2025 is the largest year in the 2022 to 2025 span.
Operating results moved from an operating loss of KRW 13.9 billion in 2022, KRW 7.38 billion in 2023 and KRW 5.57 billion in 2024, with the losses narrowing each year, to an operating profit of KRW 453 million in 2025. The operating margin shifted from -151.7% in 2022 to 1.7% in 2025.
Net income attributable to controlling shareholders rose to KRW 16.6 billion in 2023 (up 785.6%), then turned into a loss of KRW 7.65 billion in 2024 and narrowed to a loss of KRW 2.85 billion in 2025.
For 2024, the audited net loss came in wider than the pre-audit figure in the securities filing; the company attributed the gap to accounting losses from derivative valuation and provision rate adjustments.
The company also said the 2025 net loss reflected accounting valuation losses on convertible bonds and other instruments. Operating cash flow was -KRW 6.59 billion in 2022, -KRW 3.92 billion in 2023 and -KRW 5 billion in 2024, then widened to -KRW 17.2 billion in 2025.
Quarterly revenue climbed from KRW 6.95 billion in the third quarter of 2025 to KRW 9.58 billion in the fourth quarter (up 37.8% from the prior quarter), then moved to KRW 8.06 billion in the first quarter of 2026 (down 15.9%), KRW 8.22 billion in the second quarter, and KRW 6.13 billion in the third quarter (down 25.4%).
Operating profit of KRW 600 million in the fourth quarter of 2025 was followed by operating losses of KRW 2.35 billion, KRW 13.5 billion and KRW 9.48 billion in the first three quarters of 2026, three straight quarters of losses.
For the first-quarter 2026 loss, the company cited costs concentrated on future revenue sources, including global clinical expansion of its AI cartilage regeneration platform, kidney prediction diagnostics and regulatory response.